Jüri Teras

Safety and Efficacy of Tigecycline in Treatment of Skin and Skin Structure Infections: Results of a Double-Blind Phase 3 Comparison Study with Vancomycin-Aztreonam

Johannes Breedt, Jüri Teras, Jānis Gardovskis et al. · Antimicrobial Agents and Chemotherapy · 2005 · 190 citations · Full text

Double-blind Phase 3, Health Sciences, Antimicrobial Stewardship +13

A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae

Krasimir Vasilev, Galina Reshedko, Remus Orăsan et al. · Journal of Antimicrobial Chemotherapy · 2008 · 101 citations · Full text

Tetratrichomonads from the oral cavity and respiratory tract of humans

Kateřina Kutišová, J. Kulda, Ivan Čepička et al. · Parasitology · 2005 · 64 citations

Biology, Microbial Systematics, Allergy +12

Active surveillance of patients who have sentinel node positive melanoma: An international, multi‐institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT‐2)

Kristy K. Broman, Tasha M. Hughes, Lesly A. Dossett et al. · Cancer · 2021 · 60 citations · Full text

2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: long-term follow-up of a multicentre, randomised trial

Deborah Utjés, Jonas Malmstedt, Jüri Teras et al. · The Lancet · 2019 · 57 citations

Surgical Oncology, Melanoma, Surgery +5